share_log

Puma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results

Benzinga ·  Dec 23 09:04
Puma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment